isopropyl alcohol + moroctocog alfa

**isopropyl alcohol + moroctocog alfa** refers to the co-packaged presentation associated with **Xyntha**, containing recombinant factor VIII **moroctocog alfa** for intravenous replacement therapy in hemophilia A together with **isopropyl alcohol** supplied as an alcohol prep component for skin antisepsis during administration. The therapeutically active disease-treating component is moroctocog alfa, a recombinant antihemophilic factor that replaces deficient factor VIII and restores intrinsic coagulation by functioning as a cofactor for factor IXa in the activation of factor X, thereby improving thrombin generation and clot formation in patients with congenital factor VIII deficiency. Xyntha was developed by Wyeth and is marketed by Pfizer for on-demand control of bleeding, perioperative management, and routine prophylaxis in adults and children with hemophilia A; it is not indicated for von Willebrand disease. Isopropyl alcohol in this context is not the systemic therapeutic agent for hemophilia but an administration-associated antiseptic component of the product presentation.

Brand names

Xyntha

Other names

antihemophilic factor recombinant + isopropyl alcoholmoroctocog alfa + isopropyl alcohol